189 related articles for article (PubMed ID: 24446252)
1. Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients.
Xu YC; Liu Q; Dai JQ; Yin ZQ; Tang L; Ma Y; Lin XL; Wang HX
Med Oncol; 2014 Mar; 31(3):764. PubMed ID: 24446252
[TBL] [Abstract][Full Text] [Related]
2. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma.
Zhang Y; Zhu J; Tang Y; Li F; Zhou H; Peng B; Zhou C; Fu R
Diagn Pathol; 2011 Jun; 6():49. PubMed ID: 21645409
[TBL] [Abstract][Full Text] [Related]
3. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
[TBL] [Abstract][Full Text] [Related]
5. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
7. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
Park MH; Kwon HJ; Kim JR; Lee B; Lee SJ; Bae YK
Ann Surg Oncol; 2017 Nov; 24(12):3780-3787. PubMed ID: 28634667
[TBL] [Abstract][Full Text] [Related]
8. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
[TBL] [Abstract][Full Text] [Related]
9. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
[TBL] [Abstract][Full Text] [Related]
10. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
11. Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer.
Wu MQ; Hu P; Gao J; Wei WD; Xiao XS; Tang HL; Li X; Ge QD; Jia WH; Liu RB; Xie XM
Asian Pac J Cancer Prev; 2013; 14(1):287-92. PubMed ID: 23534739
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Enomoto Y; Yamashita S; Yoshinaga Y; Fukami Y; Miyahara S; Nabeshima K; Iwasaki A
Tumour Biol; 2014 Nov; 35(11):11021-5. PubMed ID: 25095982
[TBL] [Abstract][Full Text] [Related]
15. Relationship between IL-10 expression and prognosis in patients with primary breast cancer.
Li Y; Gao P; Yang J; Yu H; Zhu Y; Si W
Tumour Biol; 2014 Nov; 35(11):11533-40. PubMed ID: 25129439
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
17. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
18. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.
Turashvili G; McKinney SE; Goktepe O; Leung SC; Huntsman DG; Gelmon KA; Los G; Rejto PA; Aparicio SA
Mod Pathol; 2011 Jan; 24(1):64-81. PubMed ID: 20852590
[TBL] [Abstract][Full Text] [Related]
19. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
20. High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
Li Y; Qin J; Wu J; Dai X; Xu J
Breast Cancer Res Treat; 2020 Jul; 182(1):35-46. PubMed ID: 32424721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
